• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nanobiotix S.A.

    11/16/23 4:02:02 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    SC 13G 1 d568772dsc13g.htm SC 13G SC 13G

    CUSIP No. 63009J107

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No.    )1

     

     

    Nanobiotix S.A.

    (Name of Issuer)

    Ordinary Shares, €0.03 nominal value per share

    (Title of Class of Securities)

    63009J107*

    (CUSIP Number)

    November 9, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    *

    This CUSIP Number applies to the Issuer’s American Depositary Shares, each representing one Ordinary Share. No CUSIP Number has been assigned to the Ordinary Shares.

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

    1 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 63009J107

     

      1.    

      NAME OF REPORTING PERSON

     

      Johnson & Johnson Innovation-JJDC, Inc.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      -0-

       6.  

      SHARED VOTING POWER

     

      4,722,560 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      -0-

       8.  

      SHARED DISPOSITIVE POWER

     

      4,722,560 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,722,560 (1)

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.2% (2)

    12.  

      TYPE OF REPORTING PERSON

     

      CO

     

    (1)

    Held as American Depositary Shares, each representing one Ordinary Share.

    (2)

    Based on 46,232,072 Ordinary Shares outstanding as of November 7, 2023, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on November 9, 2023.

     

    2


    CUSIP No. 63009J107

     

      1.    

      NAME OF REPORTING PERSON

     

      Johnson & Johnson

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      New Jersey

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      -0-

       6.  

      SHARED VOTING POWER

     

      4,722,560 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      -0-

       8.  

      SHARED DISPOSITIVE POWER

     

      4,722,560 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,722,560 (1)

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.2% (2)

    12.  

      TYPE OF REPORTING PERSON

     

      CO

     

    (1)

    Held as American Depositary Shares, each representing one Ordinary Share.

    (2)

    Based on 46,232,072 Ordinary Shares outstanding as of November 7, 2023, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on November 9, 2023.

     

    3


    CUSIP No. 63009J107

     

    SCHEDULE 13G

     

    ITEM 1(a)

    NAME OF ISSUER:

    Nanobiotix S.A.

     

    ITEM 1(b)

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

    60 Rue de Wattignies, 75012 Paris, France

     

    ITEM 2(a)

    NAME OF PERSON FILING:

    This statement is being filed by Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”), and Johnson & Johnson, a New Jersey corporation (“J&J”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by JJDC and J&J are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between JJDC and J&J is attached hereto as Exhibit A.

     

    ITEM 2(b)

    ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    JJDC: 410 George Street, New Brunswick, NJ 08901

    J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933

     

    ITEM 2(c)

    CITIZENSHIP:

    JJDC: Delaware

    J&J: New Jersey

     

    ITEM 2(d)

    TITLE OF CLASS OF SECURITIES:

    Ordinary Shares, €0.03 nominal value per share (“Ordinary Shares”)

     

    ITEM 2(e)

    CUSIP NUMBER:

    63009J107

    This CUSIP Number applies to the Issuer’s American Depositary Shares, each representing one Ordinary Share. No CUSIP Number has been assigned to the Ordinary Shares.

     

    4


    CUSIP No. 63009J107

     

    ITEM 3

    STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):

    Not applicable.

     

    ITEM 4

    OWNERSHIP:

    The information set forth in the cover pages of this Schedule 13G is incorporated herein by reference.

     

    ITEM 5

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

    Not applicable.

     

    ITEM 6

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

    Not applicable.

     

    ITEM 7

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:

    Not applicable.

     

    ITEM 8

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

    Not applicable.

     

    ITEM 9

    NOTICE OF DISSOLUTION OF GROUP:

    Not applicable.

     

    ITEM 10

    CERTIFICATION:

    By signing below the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5


    CUSIP No. 63009J107

     

    SIGNATURE

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 16, 2023

     

    JOHNSON & JOHNSON INNOVATION-JJDC, INC.
    By:  

    /s/ Jill McManus

    Name:   Jill McManus
    Title:   Assistant Treasurer

     

    JOHNSON & JOHNSON
    By:  

    /s/ Marc Larkins

    Name:   Marc Larkins
    Title:   Secretary

     

    6

    Get the next $NBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings

    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Nanobiotix with a new price target

      Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

      8/28/24 7:51:18 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Nanobiotix with a new price target

      Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00

      12/8/23 8:52:29 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Financials

    Live finance-specific insights

    See more
    • Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

      Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

      5/5/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

      Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

      4/30/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

      Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3)Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launchedCash r

      4/2/25 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    SEC Filings

    See more
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/28/25 6:00:09 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/27/25 1:07:40 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/27/25 7:27:55 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

      PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the

      6/12/24 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

      PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market. This release will be followed by a conference on Wednesday, September 27, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's half-year results and provide an update on business activiti

      9/19/23 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

      PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology. "We are pleased to welcome Dr. Kayitalire to our executive leadership team at this pivotal moment for the development and commercialization of potential first-in-class radioenhancer NBTXR3," sa

      9/5/23 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

      PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 3:45 pm EDT / 9:45 pm CESTLocation: New York, NYPresenters: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the events page of the Investors sect

      5/28/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Provides First Quarter 2025 Operational and Financial Update

      Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumorsStrengthened financial position through an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) which extended cash runway into mid-2026 and permanently reduced operational cash burn€39.8 million in cash and cash equival

      5/21/25 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

      PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm EDT / 11:00 pm CESTLocation: New York, NYPresenters: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the eve

      5/12/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/9/24 5:07:50 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/8/24 8:27:02 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/2/24 4:32:27 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care